首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1425077

生物銀行市場 – 2024 年至 2029 年預測

Biobanking Market - Forecasts from 2024 to 2029

出版日期: 2024年01月23日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2022年生物銀行市值為607.35億美元，複合年成長率為5.68%，到2029年市場規模將達到894.11億美元。

生物銀行的過程涉及收集和儲存可用於研究、生物多樣性研究和診斷的生物樣本。生物樣本庫對於支持生物醫學研究、提供個人化治療以及保持最新的年齡人口統計記錄至關重要。

生物銀行市場促進因素

該行業受到對尖端治療方法研究和開發的大量投資的推動，包括個人化醫療、再生醫學和癌症基因組學研究。此外，大流行的出現使生物樣本庫處於大流行對策的最前沿，推動了生物樣本庫市場的有機收益成長。生物銀行對於診斷各種疾病和開發治療藥物至關重要。國際社會迫切需要努力生產疫苗和其他藥物來阻止病毒的傳播。

慢性病流行

近年來，由於患者生活方式和飲食習慣的改變，慢性病迅速增加。例如，根據世界衛生組織（WHO）的報告，心血管疾病是全球第一大死因。除此之外，人口老化的加劇以及肥胖和糖尿病患者數量的增加是生物樣本庫產業的主要驅動力。心血管和神經系統疾病盛行率的增加預計也將推動生物樣本庫市場的發展。這些疾病導致的死亡風險增加也增加了醫療診斷的使用。

政府舉措不斷增多

生物樣本庫樣本申請的增加、商業和公共機構對生物銀行的融資增加、生物銀行是全球生物樣本庫市場成長的主要驅動力。例如，2021 年 1 月，聯邦教育和研究部承諾在三年內提供 350 萬歐元貸款，以支持德國生物銀行節點活動。此外，維多利亞州政府於 2021 年 5 月向 Doherty 研究所的 COVID-19 生物庫提供了 500 萬美元。

基因組研究活動的增加

推動全球生物樣本庫市場擴張的主要原因之一是疾病研究基因組研究舉措的增加。為了各種健康益處而保存嬰兒臍帶血幹細胞的日益成長的趨勢以及再生醫學研究的公共和私人資金籌措正在推動生物樣本庫市場的成長。此外，世界範圍內嚴重疾病的日益流行以及對具有成本效益的藥物開發的需求也正在影響市場。此外，生物銀行市場也受到生物技術產業的成長、醫療保健產業的進步、人口成長、醫療保健支出增加以及生物銀行的突破性進展的有利影響。

血液製品生物銀行

預計在預測期內血液製品將會增加。這是由於意外和血液疾病的增加。血液和血液製品是最常被採集的檢體，也是 DNA 和 RNA 的一級資訊來源，目前佔據了生物樣本庫市場的大部分。血液相關產品的需求以及血液相關疾病盛行率的上升正在推動血液產品的擴張。此外，老年人口的增加是推動血液製品生物樣本庫市場成長的主要因素。

虛擬生物庫受歡迎

從傳統生物庫中儲存的樣本中收集和表徵的資料將在虛擬儲存庫中提供。虛擬生物庫資料庫提供樣本的高解析度照片和其他識別資訊。虛擬生物庫經常用於生物資訊學，包含有價值的臨床切片檢查樣本的 2D 和 3D 顯微鏡記錄。這種方法已成為提高樣本可見性和可訪問性的可行選擇。虛擬生物樣本庫使研究人員能夠找到管理和簡化生物銀行流程中關鍵步驟所需的產品和服務。生物樣本庫市場的未來成長可能來自虛擬系統整合。

再生醫學的採用增加

再生療法誘導細胞、組織和器官的再生並支持功能恢復。每年，都會向食品藥物管理局(FDA) 提交多項再生醫學人體臨床試驗請求。全球生物樣本庫市場的快速擴張可能歸因於再生醫學行業開發慢性疾病有效治療方法的能力。生物樣本庫為研究、開發和治療提供樣本，使其成為再生療法開發的寶貴資源。投資生物銀行可以顯著回收成本，以支持組織工程和再生醫學計畫。

預計歐洲將佔據生物銀行市場的最大佔有率

預計歐洲將佔據生物樣本庫產業的最大佔有率。丹麥、挪威和瑞典等歐洲國家都已建立生物樣本庫，為生物樣本庫市場的成長做出了重大貢獻。因此，由於歐洲樣本供應的增加，生物銀行領域不斷擴大。近年來，生物樣本庫市場的擴張是由製藥公司研發支出的增加以及歐洲虛擬生物銀行技術的日益使用所推動的。

The process of biobanking involves gathering and preserving biological samples that can later be utilised for research, studies of biodiversity, and diagnostics. To support biomedical research investigations, provide personalised treatment, and keep age demographic records current, biobanks are essential.

Driving factors for the biobanking market

The field is being driven by significant investments in the research and development of cutting-edge therapeutics including personalised medicine, regenerative medicine, and cancer genomic investigations. Additionally, the emergence of the pandemic has positioned biobanks at the forefront of pandemic control efforts, propelling the bio-banking market's organic revenue growth. For the diagnosis and creation of medications for a range of illnesses, biobanking is crucial. There has been an urgent need for international initiatives to generate vaccinations and other medications to stop the spread of the virus.

Growing prevalence of chronic diseases

Chronic diseases have grown exponentially in recent years owing to the changing lifestyle and eating habits of patients. For instance, according to the World Health Organization report, cardiovascular disease is considered the leading cause of death globally. In addition to this, the rising geriatric population and, the increase in the number of people suffering from obesity, and diabetes are the key drivers for the bio-banking industry. An increase in the prevalence of cardiovascular and neurological disorders is also anticipated to fuel the bio-banking market. The rise in mortality risk with such disorders is also increasing the utilization of medical diagnosis.

Rising government initiatives

Increased applications for biobanked samples, increased financing for biobanking from commercial & public organisations, increased genomic research efforts, and increased investment in R&D activities by various healthcare firms are the main drivers of bio-banking market growth for biobanking globally. For instance, in January 2021, the Federal Ministry of Education and Research committed €3.5 million in financing for three years to support the German Biobank Node activity. Additionally, the Victorian government gave the COVID-19 biobank at the Doherty Institute $5 million in May 2021.

Increase in genomic research activities

One of the key reasons fueling the expansion of the global bio-banking market is the rise in genomic research initiatives for the study of illnesses. The growing trend of preserving babies' cord blood stem cells for different health benefits, as well as public and private financing for regenerative medicine research, is driving the bio-banking market growth. The market is further influenced by the rise in the prevalence of major illnesses worldwide and the demand for cost-effective medication development. Additionally, the bio-banking market is favourably impacted by the growth of the biotechnology industry, improvements in the healthcare industry, population growth, an increase in healthcare spending, and breakthroughs in biobanking.

Biobanking for blood products

Blood products are expected to rise during the forecast period. This is explained by an increase in the occurrence of accidents and haematological illnesses. As the most frequently collected specimens and the primary sources of DNA and RNA, blood and blood products now account for the lion's share of the bio-banking market. The need for blood-related goods and the rising prevalence of blood-related illnesses are driving the expansion of blood products. Additionally, the growing elderly population is a major factor fueling the bio-banking market growth for blood products.

Virtual biobanks are gaining popularity

Data that has been collected and characterised from samples kept in conventional biobanks is made available in a virtual repository. The database of the virtual biobank provides high-resolution photographs of the samples and other identifying information. Virtual biobanks, which are frequently used in bioinformatics, include records for 2D and 3D microscopy on priceless clinical biopsy samples. This approach has become a viable choice for enhancing sample visibility and accessibility. Researchers may find the goods and services they require to manage and streamline key steps in the biobanking process by using virtual biobanks. Future growth of the bio-banking market is probably due to virtual system integration.

Rising adoption of regenerative drugs

Regenerative treatments aid in the induction of cell, tissue, and organ regeneration to assist them to regain their functionality. Every year, several requests for human clinical studies in regenerative medicine are submitted to the Food and Drug Administration (FDA). The rapid expansion of the global bio-banking market might be attributed to the regenerative medicine industry's ability to develop efficient treatments for chronic illnesses. The biobank has been a valuable resource for the development of regenerative therapies since it offers samples for study, development, and treatment. Investing in biobanking can result in significant cost recovery to support programmes for tissue engineering and regenerative medicine.

Europe is predicted to hold the largest market share for the biobanking market

Europe is anticipated to hold the largest share of the bio-banking industry. Well-established biobanks are present in European nations including Denmark, Norway, and Sweden, which has made a substantial contribution to the bio-banking market growth. Consequently, the biobanking sector has expanded as a result of the increasing sample supply in Europe. The bio-banking market expansion over the past few years has been aided by growing pharmaceutical company spending in R&D and greater usage of virtual biobanking technology in Europe.

Market Key Developments

In May 2023, The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) established a genetic "biobank" to learn how a patient's genetic makeup may affect the safety of their medications.
In March 2023, Biodiversity Biobanks South Africa (BBSA) was established to manage and preserve biodiversity samples.
In June 2022, Mars Petcare revealed an unprecedented research project intended to advance knowledge of pet health and illness and support the development of individualised pet healthcare by scientists and veterinarians.

Segmentation:

By Sample Type

Blood Products
Human Tissues
Cell Lines
Nucleic Acids
Biological Fluids
Human Waste Products

By Ownership

Universities
National/Regional Agencies
Non-Profit Organizations
Private Organizations

By Application

Regenerative Medicine
Life Science Research
Clinical Research

By End-Use

Pharmaceutical Companies
Academic & Research Institutes
Hospitals

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. BIOBANKING MARKET, BY SAMPLE TYPE

5.1. Introduction
5.2. Blood Products
5.3. Human Tissues
5.4. Cell Lines
5.5. Nucleic Acids
5.6. Biological Fluids
5.7. Human Waste Products

6. BIOBANKING MARKET, BY OWNERSHIP

6.1. Introduction
6.2. Universities
6.3. National/Regional Agencies
6.4. Non-Profit Organizations
6.5. Private Organizations

7. BIOBANKING MARKET, BY APPLICATION

7.1. Introduction
7.2. Regenerative Medicine
7.3. Life Science Research
7.4. Clinical Research

8. BIOBANKING MARKET, BY END-USE

8.1. Introduction
8.2. Pharmaceutical Companies
8.3. Academic & Research Institutes
8.4. Hospitals

9. BIOBANKING MARKET, BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. United States
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Others
9.5. The Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others